全文获取类型
收费全文 | 1680篇 |
免费 | 174篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 24篇 |
妇产科学 | 29篇 |
基础医学 | 133篇 |
口腔科学 | 53篇 |
临床医学 | 110篇 |
内科学 | 441篇 |
皮肤病学 | 19篇 |
神经病学 | 93篇 |
特种医学 | 39篇 |
外科学 | 186篇 |
综合类 | 3篇 |
预防医学 | 85篇 |
眼科学 | 28篇 |
药学 | 105篇 |
中国医学 | 13篇 |
肿瘤学 | 491篇 |
出版年
2023年 | 6篇 |
2022年 | 10篇 |
2021年 | 44篇 |
2020年 | 32篇 |
2019年 | 35篇 |
2018年 | 52篇 |
2017年 | 39篇 |
2016年 | 36篇 |
2015年 | 69篇 |
2014年 | 72篇 |
2013年 | 99篇 |
2012年 | 123篇 |
2011年 | 145篇 |
2010年 | 67篇 |
2009年 | 54篇 |
2008年 | 103篇 |
2007年 | 109篇 |
2006年 | 102篇 |
2005年 | 70篇 |
2004年 | 79篇 |
2003年 | 102篇 |
2002年 | 70篇 |
2001年 | 54篇 |
2000年 | 42篇 |
1999年 | 48篇 |
1998年 | 12篇 |
1997年 | 7篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1993年 | 8篇 |
1992年 | 13篇 |
1991年 | 12篇 |
1990年 | 11篇 |
1989年 | 11篇 |
1988年 | 8篇 |
1987年 | 5篇 |
1986年 | 12篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1974年 | 3篇 |
1973年 | 7篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1969年 | 5篇 |
排序方式: 共有1857条查询结果,搜索用时 15 毫秒
71.
72.
刘凯 《世界核心医学期刊文摘》2006,2(5):33-34
目的:先天性膈疝(CDH)的后遗症持续时间远远超出围生期。50%的患者发生膈疝复发或小肠梗阻(SBO)。最近,生物活性修补材料的应用渐成趋势。作者对本研究所应用不同的补片修补术治疗的CDH患者及其与上述并发症之间的关系进行回顾。方法:回顾研究152例CDH患儿的医疗记录。对接受补 相似文献
73.
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. 总被引:4,自引:0,他引:4
Francis J Giles Guillermo Garcia-Manero Jorge E Cortes Sharyn D Baker Carol B Miller Susan M O'Brien Deborah A Thomas Michael Andreeff Carol Bivins Jacques Jolivet Hagop M Kantarjian 《Journal of clinical oncology》2002,20(3):656-664
PURPOSE: To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia. PATIENTS AND METHODS: Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m(2)/d (40 mg/m(2) per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy. RESULTS: Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease. CONCLUSION: Troxacitabine has significant antileukemic activity in patients with AML and CML-BP. 相似文献
74.
75.
76.
77.
78.
Caro Schaake-Koning Lon Schuster-Uitterhoeve Guus Hart Dionisio Gonzalez Gonzalez 《International journal of radiation oncology, biology, physics》1983,9(7):1023-1028
A retrospective study was made of the results of high dose radiotherapy (≥50 Gy) given to 171 patients with inoperable, intrathoracic non small cell lung cancer from January 1971–April 1973. Local control was dependent on the total tumor dose: after one year local control was 63% for patients treated with >65 Gy, the two year local control was 35%. If treated with <65 Gy the one year local control was ≤40%. Tumor doses correlated with the size of the booster field. If the size of the booster field was <100 cm2, the one year local control was 72%; the two year local control was 44%. Local control was also influenced by the performance status, by the localization of the primary tumor in the left upper lobe and in the periphery of the lung. Local control for tumors in the left upper lobe and in the periphery of the lung was about 70% after one year, and about 40% after two years. The one and two years survival results were correlated with the factors influencing local control. The dose factor, the localization factors and the performance influenced local control independently. Tumors localized in the left upper lobe did metastasize less than tumors in the lower lobe, or in a combination of the two. This was not true for the right upper lobe. No correlation between the TNM system, pathology and the prognosis were found. 相似文献
79.
80.
Tormo JR DePedro N Royo I Barrachina I Zafra-Polo MC Cuadrillero C Hernández P Cortes D Peláez F 《Oncology research》2005,15(3):129-138